Reasons to be optimistic after slow start to the year We expect Elanders to report Q2 net sales of S...
Earnings capacity IFPM +3.5% vs ABGSCe Eastnine delivered a Q2 report with rental income of EUR 9.
Yesterday after close Acarix announced a SEK21m directed share issue targeting US based family offic...
Förvaltningsresultat ökade med 26% på årsbasis drivet av främst ränteintäkter.
Duell’s Q3 development was two-fold as growth in Europe was stronger than expected while revenue dec...
Q2'24e expectations We forecast flat (0%) organic growth rate for Vitrolife and a marginally higher ...
Redeye comments on AVTECH’s key figures, which came in 5% ahead on net sales and 25% on EBITDA, sugg...
Redeye comments on W5’s announcement of a major framework agreement for generators worth up to SEK50...
Redeye presents its preview for Devyser Diagnostics’ Q2 2024 report, due on July 23.
IRLAB Therapeutics has successfully completed the second and final of two pre-determined safety and ...
Redeye presents its preview of Sedana Medical’s Q2 2024 report, due on July 23.
Refine Group AB ("Refine", "Koncernen" eller "Bolaget") meddelade den 28 juni år 2024 att dotterbola...
Profitability below expectations Duell’s Q3 net sales came in at EUR 37.
Redeye initiates coverage on CoinShares (CS), a leading crypto asset manager holding a European mark...
Railcare säkrar tillgång till framtidssäkrade lok genom innovativ affär.
Luxbright har levererat en första leverans av ett kundspecifikt röntgenrör till Fisica Inc.
Redeye updates its estimates ahead of the Q2 report following today’s announced 5G order.
Cereno Scientific has released updates on its two most advanced clinical programmes.
Redeye offers a preview of Doro's Q2 results set to be released on July 17th.
Redeye offers a preview of Advenica's Q2 results set to be released on July 19th.
